An Open-Label, Randomized, 3-Way Crossover, Single-Dose Study in Healthy Volunteers Comparing the Bioavailability of CMX001 (HDP-Cidofovir Conjugate) Delivered as a Tablet Formulation vs a Solution Formulation and the Effect of Food on CMX001 Bioavailability.

Trial Profile

An Open-Label, Randomized, 3-Way Crossover, Single-Dose Study in Healthy Volunteers Comparing the Bioavailability of CMX001 (HDP-Cidofovir Conjugate) Delivered as a Tablet Formulation vs a Solution Formulation and the Effect of Food on CMX001 Bioavailability.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2014

At a glance

  • Drugs Brincidofovir (Primary) ; Brincidofovir (Primary)
  • Indications Cytomegalovirus infections; Herpes simplex virus infections; Human papillomavirus infections; Human polyomavirus infections; Smallpox
  • Focus Pharmacokinetics
  • Most Recent Events

    • 03 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Jan 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 15 Nov 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top